



Dear Colleagues,

Today, some of the Indian media featured articles about a second whistleblower complaint filed against our company to the market regulator, Securities and Exchange Board of India (SEBI). We are aware that an online news portal (moneylife.com) is alleging that they are privy to the whistleblower documents & other confidential emails and are also sharing them with institutional investors for inspection.

We have requested SEBI to examine the role of some media houses in spreading unsubstantiated information leading to unnecessary speculation.

So far the company has received two queries from SEBI which we have responded to. But we can't say whether the queries are related to the whistleblower complaint. We are committed to provide all relevant details to SEBI, if and when approached by them.

At Sun, we remain committed to follow the highest levels of corporate governance. We request all colleagues to refrain from discussing or speculating about these matters internally as well as externally. Let's not get distracted by these developments and remain focussed on meeting our business goals for the year.

If you receive any queries on this matter from external stakeholders, please contact Gaurav Chugh from Corporate Communications (Mob: +91 98104 71414; Email: gaurav.chugh@sunpharma.com).

Best Regards,

Dilip Shanghvi